PDCD1 and non-small cell lung carcinoma: Immune-checkpoint inhibitors (mainly antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death protein-1 (PD-1) and its ligand (PD-L1)) have emerged as potent therapies against some solid tumors such as melanoma and advanced non-small cell lung cancer (NSCLC)21,22.